Comparison
17 20 Lyase Deficiency Isolated Included CN372394 vs 11q22 2q22 3 Microdeletion Syndrome C5680062
Clinical comparison between 17 20 Lyase Deficiency Isolated Included CN372394 and 11q22 2q22 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
6 comparison axes
Onset
17 20 Lyase Deficiency Isolated Included CN372394
0-16
11q22 2q22 3 Microdeletion Syndrome C5680062
0-null
Onset patterns differ
Severity
17 20 Lyase Deficiency Isolated Included CN372394
severe
11q22 2q22 3 Microdeletion Syndrome C5680062
moderate
Different severity levels
Chronic
17 20 Lyase Deficiency Isolated Included CN372394
Chronic
11q22 2q22 3 Microdeletion Syndrome C5680062
Chronic
Differing course
Communicable
17 20 Lyase Deficiency Isolated Included CN372394
No
11q22 2q22 3 Microdeletion Syndrome C5680062
No
Different transmission
Body System
17 20 Lyase Deficiency Isolated Included CN372394
endocrine
11q22 2q22 3 Microdeletion Syndrome C5680062
congenital
Same/different system
Category
17 20 Lyase Deficiency Isolated Included CN372394
endocrine
11q22 2q22 3 Microdeletion Syndrome C5680062
genetic
Different category
Bottom line
17-20-lyase-deficiency-isolated-included-CN372394 and 11q22-2q22-3-microdeletion-syndrome-C5680062 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 20 Lyase Deficiency Isolated Included CN372394 | 11q22 2q22 3 Microdeletion Syndrome C5680062 | Discriminating power |
|---|---|---|---|
| Main clinical domain | Endocrine concern involving sex-steroid synthesis | Congenital developmental and variable health concerns | High |
| Reported onset | Supplied onset spans birth to age 16 | Congenital onset; later timing is unspecified | Moderate |
| Severity pattern | Rated severe in the supplied axis | Rated moderate in the supplied axis | Moderate |
When to favor each condition
Choose 17 20 Lyase Deficiency Isolated Included CN372394 when
Suspected disordered puberty or sex development
The left concept is categorized as an endocrine disorder
Moderate
Steroid enzyme defect is more likely than a deletion
The conditions have different proposed causes
High
Evaluation occurs from birth through adolescence
The supplied onset range for the left concept is 0–16
Low
Choose 11q22 2q22 3 Microdeletion Syndrome C5680062 when
Developmental concerns suggest a chromosomal condition
The right concept is a genetic microdeletion syndrome
Moderate
Testing indicates loss at 11q22.2–q22.3
The deletion itself is central to this diagnosis
High
Care is focused on congenital symptoms
The source describes supportive, symptom-based management
Moderate
How key tests differ
| Test | 17 20 Lyase Deficiency Isolated Included CN372394 | 11q22 2q22 3 Microdeletion Syndrome C5680062 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | Sex-steroid abnormalities may occur; cutoffs are not established | No defining hormone pattern is established | An abnormal result needs endocrine interpretation and is not itself a diagnosis |
| Chromosomal microarray | Not expected to establish isolated lyase deficiency | May detect the 11q22.2–q22.3 deletion | A copy-number finding requires genetics confirmation |
| Targeted gene evaluation | May be considered for the suspected steroid pathway | Does not replace testing for the deletion | Selection should follow the phenotype and specialist judgment |
Prognosis comparison
17 20 Lyase Deficiency Isolated Included CN372394
- Outcome
- Long-term outcome is not established; the supplied course is chronic and severe.
- Factors
- Hormone effects, age at recognition, and associated features may matter.
11q22 2q22 3 Microdeletion Syndrome C5680062
- Outcome
- Long-term outcome is not established; the supplied course is chronic and moderate.
- Factors
- Deleted content, development, and associated health concerns may vary.
Time frame: A lifelong course is suggested, but exact timelines are not established.
Cause, severity, complications, and available support should guide counseling.
Complications comparison
| Complication | Presentation |
|---|---|
| Sex development effects | Impaired sex-steroid effects are plausible; spectrum is not established Specific effects are not established in the supplied data Do not assume the conditions share genital findings |
| Developmental concerns | Not identified as the primary supplied feature Development may be affected, with variable severity Developmental concerns do not establish lyase deficiency |
| Chronic disease burden | Chronic course rated severe Chronic course rated moderate Individual outcomes cannot be inferred from these ratings alone |
Patient education highlights
- HighDifferent causes
One is an endocrine steroid-pathway disorder; the other is a missing chromosome 11 segment. They are not interchangeable.
- HighResults versus diagnosis
Hormone abnormalities or a microarray finding require clinician interpretation before either diagnosis is made.
- MediumDifferent care focus
Endocrine follow-up may apply to the left; supportive symptom care is described for the right. No treatment doses are established here.